Abeona Therapeutics announces favorable medicare reimbursement decisions

Abeona Therapeutics announced that the Centers for Medicare and Medicaid Services, CMS, has granted a product-specific procedure code ICD-10-PCS for prademagene zamikeracel (pz-cel), Abeona’s investigational autologous cell-based gene therapy currently in development for recessive dystrophic epidermolysis bullosa, RDEB. If pz-cel receives U.S. marketing approval, this code will allow for efficient and accurate documentation, billing, and analysis of inpatient hospital procedures using pz-cel. The code will go into effect on October 1, 2024.